New asthma drug JYB1904 shows promise in early trial
NCT ID NCT06438757
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug, JYB1904, in 69 adults with allergic asthma. Participants received either JYB1904 every 8 weeks or the standard drug omalizumab every 2 to 4 weeks for 24 weeks. The goal was to see how the drug behaves in the body, how safe it is, and how well it controls asthma symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JYB1904 (a biologic drug targeting IgE, similar to omalizumab)
What this could lead to
If successful, JYB1904 could offer a new treatment option for allergic asthma, potentially requiring fewer injections than current therapies.
What could go wrong
This is an early Phase IIa trial with only 69 participants, so results may not confirm effectiveness or safety. The drug may not work better than existing treatments or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 201203, China